期刊文献+

卵巢癌化疗患者紫杉醇血药浓度监测的临床价值 被引量:5

Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer
下载PDF
导出
摘要 目的研究卵巢癌患者化疗后,紫杉醇(PTX)血药浓度与疗效及不良反应的相关性。方法75例卵巢癌患者接受PT方案(紫杉醇+卡铂)一线化疗。于每周期PTX静脉输注开始后(24±6)h采集静脉血2次,采用胶乳免疫比浊法检测PTX浓度。根据PTX血药浓度的平均值,将75例患者分为≤25 h组、(26~30)h组和≥31 h组,回顾性分析PTX血药浓度与疗效及与不良反应间的相关性。结果≤25 h组、(26~30)h组、≥31 h组PTX血药浓度分别为(22.54±2.04)h、(28.62±1.87)h、(33.01±2.84)h,差异有统计学意义(P<0.05)。随着PTX血药浓度的升高,化疗的不良反应发生率增多,程度加强(P<0.05)。(26~30)h组的有效率(31.25%)高于≤25 h组(20%)(P=0.02),与≥31 h组有效率(33.33%)相比差异无统计学意义(P=0.96)。结论卵巢癌采用紫杉醇PTX血药浓度在(26~30)h的患者疗效好,且不良反应稍低。 Objective To investigate the relationship between plasma concentration of paclitaxel(PTX) and the efficacy as well as toxic and side effects in the patients with ovarian cancer. Methods Seventy-five patients with ovarian cancer accepted PT(paclitaxel+carboplatin) chemotherapy regimen as their first line treatment. The blood samples were taken twice at(24±6)h after continuous infusion of paclitaxel in each cycle and the plasma concentration of paclitaxel was detected by latex immuno-turdidimetry. The patients were randomly assigned into three groups according to the average plasma concentration of paclitaxel: group 1(plasma concentration paclitaxel≤25h), group 2(26-30h) and group 3(≥31h). The relationship between the drug plasma concentration, therapeutic efficacy and adverse reactions in different paclitaxel plasma concentration was analyzed retrospectively. Results The average plasma concentrations of paclitaxel of the three groups were(22.54±2.04)h,(28.62±1.87)h, 33.01±2.84)h, respectively(P〈0.05). The incidence and extent of adverse reactions were significantly higher and stronger with the increasing plasma concentration of paclitaxel. The therapeutic efficacy of group 2(26-30)h was 31.25% which was better than that(20%) of group 1(≤25h)(P=0.02), but had no significant difference with that(33.33%) of group 3(≥31h)(P=0.96). Conclusion The ovarian cancer patients treated with paclitaxel-based chemotherapy with an average plasma concentration of paclitaxel between 26-30 h have a higher curative effect and lower toxic side effect.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2017年第4期268-271,共4页 Cancer Research on Prevention and Treatment
关键词 卵巢癌 紫杉醇 血药浓度 胶乳免疫比浊法 Ovarian cancer Paclitaxel Plasma concentration Latex immuno-turdidimetry
  • 相关文献

参考文献6

二级参考文献44

  • 1黄海欣,黄东宁,李桂生,杨春旭.紫杉醇联合奥沙利铂治疗30例晚期胃癌临床观察[J].肿瘤学杂志,2004,10(4):260-261. 被引量:3
  • 2王安,周宏灏.细胞色素氧化酶CYP3A4基因突变与表型研究进展[J].中国临床药理学杂志,2005,21(6):459-462. 被引量:11
  • 3李慧,任素蓉,廖东彪,周筱秋,杜小波.腹腔和静脉双途径应用紫杉醇加顺铂治疗晚期卵巢癌的临床观察[J].重庆医学,2007,36(12):1177-1178. 被引量:13
  • 4Martin N, Catalin J, Blachon MF, et al. Assay of paclitaxel (Taxol) in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl, 1998, 709: 281-288. 被引量:1
  • 5Ciccolini J, Catalin J, Blachon MF, et al. Rapid high- performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J Chromatogr B Biomed Sci Appl, 2001, 759: 299-306. 被引量:1
  • 6Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol, 2006, 24 : 3347- 3353. 被引量:1
  • 7Douillard JY, Cunnigham D, Roth AD, et al. Ifinotecan combined with fluomuracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 2000, 355:1041-1047. 被引量:1
  • 8Ychou M, Duffour J, Kramar A, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase Ⅱ study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol, 2003, 52:282-290. 被引量:1
  • 9Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil : results from a muhicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res, 1998, 4 : 2039-2045. 被引量:1
  • 10Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin : results of a muhicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol, 1998, 16:1470-1478. 被引量:1

共引文献35

同被引文献28

引证文献5

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部